Open Access

Insulin‑like growth factor‑binding proteins play a significant role in the molecular response to imatinib in chronic myeloid leukemia patients

  • Authors:
    • Yingli Ren
    • Shihong Yin
    • Ya Lin
    • Xiucai Xu
  • View Affiliations

  • Published online on: December 20, 2019     https://doi.org/10.3892/etm.2019.8364
  • Pages: 1771-1778
  • Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Imatinib (IM) is successfully used in the majority of patients with chronic myeloid leukemia (CML), but some patients develop resistance to drug treatment. Insufficient apoptosis results in uncontrolled cell proliferation, which is closely associated with the occurrence of drug resistance. Therefore, it is crucial to identify new biomarkers related to drug resistance. This aim of the present study was to investigate the profile of apoptosis‑related proteins in K562 and K562/G (IM‑resistant K562 cells) cells, in order to identify new biomarkers. A human apoptosis antibody array was used to screen 46 proteins in the two cells lines, among which 20 proteins were found to be differentially expressed between K562 and K562/G cells. The major proteins included secreted caspase‑8, insulin‑like growth factor‑binding protein (IGFBP)‑1, IGFBP‑2, IGFBP‑3, caspase‑3 and p27. IGFBP‑1 IGFBP‑2 and IGFBP‑3 were selected for the follow‑up study. Subsequently, reverse transcription‑quantitative PCR analysis and western blotting were used to detect the expression levels of the IGFBPs. The results revealed that the expression levels of IGFBP‑2 and IGFBP‑3 in K562/G cells were significantly decreased compared with those in K562 cells, whereas the IGFBP‑1 level was higher. Moreover, no significant correlation was observed between IGFBP‑1 or IGFBP‑2 and the level of the BCR‑ABL fusion protein, whereas decreasing IGFBP‑3 levels were associated with increasing BCR‑ABL levels. These results suggested that IGFBP‑1, IGFBP‑2 and IGFBP‑3 could be useful novel biomarkers for IM resistance in CML.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Ren, Y., Yin, S., Lin, Y., & Xu, X. (2020). Insulin‑like growth factor‑binding proteins play a significant role in the molecular response to imatinib in chronic myeloid leukemia patients. Experimental and Therapeutic Medicine, 19, 1771-1778. https://doi.org/10.3892/etm.2019.8364
MLA
Ren, Y., Yin, S., Lin, Y., Xu, X."Insulin‑like growth factor‑binding proteins play a significant role in the molecular response to imatinib in chronic myeloid leukemia patients". Experimental and Therapeutic Medicine 19.3 (2020): 1771-1778.
Chicago
Ren, Y., Yin, S., Lin, Y., Xu, X."Insulin‑like growth factor‑binding proteins play a significant role in the molecular response to imatinib in chronic myeloid leukemia patients". Experimental and Therapeutic Medicine 19, no. 3 (2020): 1771-1778. https://doi.org/10.3892/etm.2019.8364